- $504.78m
- -$62.82m
- $262.60m
Novartis licenses Arvinas' cancer drug for up to $1 billion
Brief: Arvinas Enters Into Transaction With Novartis, Including Global License Agreement
U.S. RESEARCH ROUNDUP-Autozone, Constellation Energy, Sterling Infrastructure
Brief: Arvinas Q4 Basic EPS USD -2.53 Vs. IBES Estimate USD -1.27
U.S. RESEARCH ROUNDUP-Home Depot, Palo Alto Networks, Wendys
Brief: Arvinas Announces Chief Financial Officer Transition
Arvinas Inc expected to post a loss of $1.28 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Adobe, United Parcel Service, ZeroFox Holdings
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Rallybio, Willis Towers Watson
U.S. STOCKS ON THE MOVE-DocuSign, Eli Lilly, Sunworks
Arvinas rises on FDA's 'fast track' tag for breast cancer therapy
Brief: Arvinas Appoints Jared Freedberg as General Counsel
U.S. STOCKS ON THE MOVE-Rockwell Automation, Crinetics Pharmaceuticals, TransUnion
U.S. STOCKS ON THE MOVE-Arvinas, FMC Corp, Wave Life Science
Arvinas rises as Wells Fargo upgrades to "overweight", raises PT
Brief: Arvinas Inc Files For Prospectus Related To 16.39 Million Shares Of Common Stock By Selling Stockholders- SEC Filing
U.S. RESEARCH ROUNDUP- Boeing, McDonald's, Quaker Houghton
U.S. RESEARCH ROUNDUP- Autozone Inc, Digital Realty Trust Inc, Equinix Inc
Brief: Arvinas And Pfizer Announce Interim Data From Phase 1B Trial Of Vepdegestrant In Combination With Palbociclib (Ibrance®) And Plans To Expand Vepdegestrant Development Program